We asked our bio­phar­ma read­ers about their com­pa­ny's poli­cies on vac­cine man­dates. Feel­ings are run­ning strong

The rapid adop­tion of Covid-19 vac­cine man­dates by sev­er­al Big Phar­ma multi­na­tion­als en­joys broad sup­port in the bio­phar­ma in­dus­try as peo­ple re­turn to the of­fice. But it’s clear that there are some deep-seat­ed ob­jec­tions among some and no clear con­sen­sus on the need for putting man­dates in place for every­one.

That’s the bot­tom line from our snap sur­vey over the last 2 days. We asked our bio­phar­ma sub­scribers whether their com­pa­nies had a man­date in place and whether or not they agreed that vac­cines should be re­quired. Paul Hast­ings, the CEO of Nkar­ta and chair­per­son of BIO — and an en­thu­si­as­tic sup­port­er of man­dates — al­so helped spread the link to the poll among the or­ga­ni­za­tion’s mem­ber­ship.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER